Editorials

How Meaningful Is Our Evaluation of Meaningful Change in Osteoarthritis?
G.A. Hawker, M.A.M. Gignac .................................................. 639

What Are Open-Label Extension Studies For?
W.J. Taylor, M. Weatherall ................................................... 642

Allogeneic Bone Marrow Transplantation for Autoimmune Disease — The Jury Is Still Out
A. Tyndall ................................................................. 644

Articles

Antibodies to Viral Citrullinated Peptide in RA
C. Anzilotti, G. Merlini, F. Pratesi, C. Tommasi,
D. Chimenti, P. Migliorini .................................................. 647

Paraarticular Trabecular Bone Loss at theUltradistal Radius and Increased Arterial Stiffening in Postmenopausal Patients with RA
K. Tanaka, M. Inaba, H. Goto, et al ...................................... 652

Comparison of 2 Doses of Etanercept (50 vs 100 mg) in Active RA: A Randomized Double Blind Study
A.K. Johnsen, M.H. Schiff, P.J. Mease, et al ........................... 659

Community-Based Evaluation of Etanercept in Patients with RA P. Farahani, M. Levine, K. Gaebel,
E.C.Y. Wang, N. Khalidi ...................................................... 665

Evidence-Based Medicine Is Affordable: The Cost-Effectiveness of Current Compared with Optimal Treatment in RA and OA G. Andrews, L. Simonella,
H. Lapsley, K. Sanderson, L. March ................................... 671

Treatment of RA Patients with Ablatacept and MTX
P. Emery, M. Kosinski, T. Li, et al ........................................ 681

Prevalence and Associated Factors for Falls in Women with Established Inflammatory Polyarthritis

Prevalence and Clinico-Serological Correlations of Anti-α-Enolase, Anti-C1q, and Anti-dsDNA Antibodies in Patients with SLE
M. Mosca, D. Chimenti, F. Pratesi, et al ................................. 695

ACE Insertion/Deletion Polymorphism and SLE: A Metaanalysis

Relationship Between IL-6 Promoter Polymorphism at Position –174, IL-6 Serum Levels, and the Risk of Relapse/Recurrence in PMR
L. Boiardi, B. Casali, E. Farnetti, et al .................................... 703

Myelopathies Secondary to SS: Treatment with Monthly IV Cyclophosphamide Associated with Corticosteroids

Continued Inhibition of Radiographic Progression in Patients with PsA Following 2 Years of Treatment with Etanercept P.J. Mease, A.J. Kivitz, F.X. Burch, et al .................. 712

Is Sulfasalazine Effective in AS? A Systematic Review of Randomized Controlled Trials J. Chen, C. Liu .............................................. 722

The Cost-Effectiveness of Infliximab (Remicade®) in the Treatment of AS in Canada G. Kobelt, P. Andlin-Sobocki,
W.P. Maksymowych ......................................................... 732

HFE Gene Mutations Are Associated with OA in the Index or Middle Finger MCP Joints
G.J. Carroll ............................................................... 741

Do Exercise and Self-Management Interventions Benefit Patients with OA of the Knee? A Metaanalytic Review
L. Devos-Comby, T. Cronan, S.C. Roesch ............................... 744

What Do OA Health Outcome Instruments Measure? Impairment, Activity Limitation, or Participation Restriction?
B. Pollard, M. Johnston, P. Diepepe ..................................... 757

Measuring the Outcome of Health Resort Programs M. Weigl, T. Ewert, J. Kleinschmidt, G. Stucki .............................. 764

Physician Control of Needle and Syringe During Aspiration-Injection Procedures with the New Reciprocating Syringe

Gastrointestinal Prophylactic Therapy AmongPatients withArthritis Treated by Rheumatology Specialists
E. Benito Garcia, K. Michaud, F. Wolfe ................................... 779

Increased Expression of N-Methyl-D-Aspartate Receptor Subunit 2D in the Skin of Patients with FM
S-H. Kim, T.J. Jang, I.S. Moon ............................................. 785

Pediatric Rheumatology

Preliminary Validation of Clinical Remission Criteria Using the OMERACT Filter for Select Categories of JIA
C.A. Wallace, A. Ravelli, B. Huang, E.H. Giannini .................... 789

Contents continued opposite inside back cover . . .